Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.  Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.  The company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.  These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.  Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.